Épisodes

  • Missed Opportunities in HIV Prevention

    Missed Opportunities in HIV Prevention
    Nov 11 2025
    Overview: In this episode, Toyin Nwafor, MD, and Christian B Ramers, MD, draw on their experience in primary care, HIV and HIV prevention to highlight missed opportunities for HIV prevention and discuss strategies to help address gaps in the HIV care continuum. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Toyin Nwafor, MD; Christian B Ramers, MD, MPH, FIDSA, AAHIVS For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus References AIDSVu.org. Prevalence in the United States. 2022. Available from: https://map.aidsvu.org/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Baeten J et al. Curr HIV/AIDS Rep 2013;10:142–51. CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 25, 2025). CDC. Discussing sexual health with your patients. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/sexual-history/index.html (Accessed June 25, 2025). CDC.gov. HIV diagnoses, deaths, and prevalence. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html (Accessed June 25, 2025). CDC. National HIV prevention and care objectives: 2025 update. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html (Accessed June 25, 2025). CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2021 update: a clinical practice guideline. 2021. Available from: https://stacks.cdc.gov/view/cdc/112360 (Accessed June 25, 2025). Doblecki-Lewis S et al. J Int Assoc Provid AIDS Care 2019;18:2325958219848848. DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025). HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 2, 2025). HIV.gov. HIV treatment as prevention. 2023. Available from: https://www.hiv.gov/tasp (Accessed June 25, 2025). HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed May 21, 2025). HIV.gov. Viral suppression and undetectable viral load. 2025. Available from: https://www.hiv.gov/hiv-basics/staying-in-hiv-care/hiv-treatment/viral-suppression (Accessed July 18, 2025). HIV.gov. Who is at risk for HIV. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/who-is-at-risk-for-hiv (Accessed June 25, 2025). Johns Hopkins Bloomberg School of Public Health. What to know about PrEP. 2025. Available from: https://publichealth.jhu.edu/2025/who-needs-prep-for-hiv-prevention (Accessed June 25, 2025). Kamis KF et al. Open Forum Infect Dis 2019;6:ofz310. KFF. HIV testing in the United States. 2024. Available from: https://www.kff.org/hiv-aids/hiv-testing-in-the-united-states/ting in the United States | KFF (Accessed August 26, 2025). NIH. HIV and sexually transmitted infections (STIs). 2021. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-sexually-transmitted-infections-stis (Accessed June 25, 2025). Ramchandani MS et al. Curr HIV/AIDS Rep 2019;16:244–56. Saag MS et al. JAMA 2018;320:379–96. Sweeney P et al. J Acquir Immune Defic Syndr 2019;82(Suppl 1):S1–5. The White House. National HIV/AIDS strategy for the United States 2022–2025. 2021. Available from: https://files.hiv.gov/s3fs-public/NHAS-2022-2025.pdf (Accessed June 25, 2025). UNAIDS.org. Recommended 2030 targets for HIV. 2025. Available from: https://www.unaids.org/en/recommended-2030-targets-for-hiv (Accessed August 26, 2025). United States Census Bureau. National population by characteristics: 2020-2024. 2024. Available from: https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html (Accessed June 25, 2025). United States Census Bureau. United States Population Growth by Region. 2025. Available from: https://www.census.gov/popclock/ (Accessed June 25, 2025). Yumori C et al. Sex Transm Dis 2021;48:32–6.
    Voir plus Voir moins
    13 min
  • PrEP Landscape Overview

    PrEP Landscape Overview
    Nov 11 2025
    Overview: In this episode, Dr Gina Brown and Dr Sahar Khalili draw on their expertise in HIV prevention to provide an overview of the current PrEP landscape in the United States. They highlight advancements in HIV prevention and emphasize the importance of targeted programs to address disparities in access and uptake across population groups and geographic regions. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Gina Brown, MD; Sahar Khalili, PharmD For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus References ACOG. Preexposure prophylaxis for the prevention of human immunodeficiency virus. 2024. Available from: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/06/preexposure-prophylaxis-for-the-prevention-of-human-immunodeficiency-virus (Accessed June 25, 2025). ADAP Directory. About. 2024. Available from: https://adap.directory/about (Accessed June 25, 2025). Aidsmap. Condoms. 2023. Available from: https://www.aidsmap.com/about-hiv/condoms#toc-how-effective-are-condoms (Accessed June 25, 2025). AIDSVu. AIDSVu releases new PrEP data and launches PrEPVu.org, a new PrEP equity platform. 2024. Available from: https://aidsvu.org/news-updates/aidsvu-releases-new-prep-data-and-launches-prepvu-org-a-new-prep-equity-platform/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. AIDSVu. AIDSVu releases 2024 PrEP use data showing growing use across the U.S. 2025. Available from: https://aidsvu.org/news-updates/aidsvu-releases-2024-prep-use-data-showing-growing-use-across-the-u-s/ (Accessed July 18, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. AIDSVu. Location profiles: South. 2025. Available from: https://map.aidsvu.org/profiles/region/south/prevention-and-testing#1-2-PnR (Accessed July 31, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. AIDSVu. PrEP use significantly associated with decreasing new HIV diagnoses across U.S. states. 2025. Available from: https://aidsvu.org/news-updates/prep-use-significantly-associated-with-decreasing-new-hiv-diagnoses-across-u-s-states/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Baeten J et al. Curr HIV/AIDS Rep 2013;10:142–51. Bekker LG et al. N Engl J Med 2024;391:1179–92. CDC. About ending the HIV epidemic in the US. 2024. Available from: https://www.cdc.gov/ehe/php/about/index.html (Accessed June 2, 2025). CDC. Clinical Guidance for PrEP. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/prep/index.html (Accessed June 25, 2025). CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update. 2021. Available from: https://stacks.cdc.gov/view/cdc/112360 (Accessed June 25, 2025). Coates TJ et al. Lancet 2008;372:669–84. DHHS. Pre-exposure (PrEP) to prevent HIV during periconception, antepartum, ad postpartum. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/perinatal-hiv/pre-exposure-prophylaxis-prep-prevent-hiv-perinatal.pdf (Accessed June 25, 2025). Gandhi RT et al. JAMA 2023;329:63–84. HIV.gov. HIV treatment as prevention. 2023. Available from: https://www.hiv.gov/tasp (Accessed June 25, 2025). HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 2, 2025). HIV.gov. Pre-exposure prophylaxis. 2025. Available from: https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis (Accessed June 25, 2025). Kelley CF et al. N Engl J Med 2025;392:1261–76. Kourtis AP et al. Ann Epidemiol 2025:106:48-54. Landers S et al. Am J Public Health 2017;107:1534–35. Landovitz RJ et al. N Engl J Med 2021;385:595–608. NIH. HIV and sexually transmitted infections (STIs). 2021. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-sexually-transmitted-diseases-stds (Accessed June 25, 2025). NIH. HIV medicines during pregnancy and childbirth. 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-medicines-during-pregnancy-and-childbirth (Accessed July 31, 2025) NIH. Post-exposure prophylaxis (PEP). 2025. Available from: https://hivinfo.nih.gov/...
    Voir plus Voir moins
    15 min
  • Rapid Start, Restart for HIV Treatment

    Rapid Start, Restart for HIV Treatment
    Nov 11 2025
    Overview: In this episode, Dr Toyin Nwafor and Dr Andrew Zolopa provide an overview of the HIV treatment landscape both globally and in the United States. They highlight the current gaps in the HIV care continuum, emphasize the importance of rapid start and viral suppression in reducing HIV transmission through sex and describe initiatives and strategies aimed at closing these gaps to help end the HIV epidemic in the United States. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Toyin Nwafor, MD; Andrew Zolopa, MD For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus References AETC. Rapid (immediate) ART initiation and restart: guide for clinicians. 2023. Available from: https://aidsetc.org/resource/rapid-immediate-art-initiation-restart-guide-clinicians (Accessed June 25, 2025). Baxter A et al. J Acquir Immune Defic Syndr 2025;99:47–54. CDC. About ending the HIV epidemic in the US. 2024. Available from: https://www.cdc.gov/ehe/php/about/index.html (Accessed June 25, 2025). CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 25, 2025). CDC. Getting tested for HIV. 2025. Available from: https://www.cdc.gov/hiv/testing/index.html#cdc_testing_why_get_tested-why-get-tested (Accessed June 25, 2025). CDC. Laboratory testing for the diagnosis of HIV infection. 2014. Available from: https://stacks.cdc.gov/view/cdc/23446 (Accessed June 25, 2025). CDC. National HIV prevention and care objectives: 2025 update. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html (Accessed June 25, 2025). Delaney KP et al. Am J Prev Med 2021;61(5 Suppl 1):S6–S15. DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025). HIV.gov. EHE overview. 2025. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview (Accessed June 25, 2025). HIV.gov. Global statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics (Accessed June 25, 2025). HIV.gov. HIV Care Continuum. 2025. Available from: https://www.hiv.gov/federal-response/other-topics/hiv-aids-care-continuum (Accessed June 25, 2025). HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 25, 2025). HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed June 25, 2025). HIV.gov. Viral suppression and undetectable viral load. 2025. Available from: https://www.hiv.gov/hiv-basics/staying-in-hiv-care/hiv-treatment/viral-suppression (Accessed June 25, 2025). Mirzazadeh A et al. PLoS Med 2022;19:e1003940. NIH. HIV testing. 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-testing (Accessed June 25, 2025). Palacio-Vieira J et al. BMC Public Health 2021;21:1596. Saag MS et al. JAMA 2018;320:379–96. The White House. National HIV/AIDS strategy for the United States 2022–2025. 2021. Available from: https://files.hiv.gov/s3fs-public/NHAS-2022-2025.pdf (Accessed June 25, 2025). WHO. Supporting re-engagement in HIV treatment services: policy brief. 2024. Available from: https://www.who.int/publications/i/item/9789240097339 (Accessed June 25, 2025).
    Voir plus Voir moins
    21 min
  • The Importance of Pan-viral Screening

    The Importance of Pan-viral Screening
    Nov 11 2025
    Overview: In this episode, Dr Melissa Jones and Dr Christian Ramers discuss the importance of pan-viral screening for HIV and hepatitis. They emphasize the need for integrated testing and prevention strategies and the current barriers to implementation. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time. Guest: Christian B Ramers, MD, MPH, FIDSA, AAHIVS; Melissa Jones, DNP, APRN-BC For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus References AASLD/IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2025. Available from: https://www.hcvguidelines.org/ (Accessed June 10, 2025). Arora DR et al. ISRN AIDS 2013;2013:287269 Alter MJ. J Hepatol 2006;44:S6–9. Bazargan M, Cobb BMS, Assari S. Ann Fam Med 2021;19:4–15. Beard N, Hill A. Open Forum Infect Dis 2024;11:ofad666. Bottero J, Boyd A, Gozlan J et al. Open Forum Infect Dis 2015;2:ofv162. Brunetto, Maurizia Rossana et al. J Hepatol 2023;79:433–60. Calabrese SK, Krakower DS, Mayer KH. Am J Public Health 2017;107:1883–89. CDC. Status neutral HIV care and service delivery eliminating stigma and reducing health disparities. 2022. Available from: https://stacks.cdc.gov/view/cdc/129024 (Accessed June 10, 2025). CDC. Clinical guidance for PrEP. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/prep/index.html (Accessed June 10, 2025). CDC. Clinical screening and diagnosis for hepatitis C. 2025. Available from: https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing (Accessed June 10, 2025). CDC. Clinical testing and diagnosis for hepatitis B. 2025. Available from: https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/ (Accessed June 10, 2025). CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 10, 2025). CDC. Getting tested for HIV. 2025. Available from: https://www.cdc.gov/hiv/testing/ (Accessed June 10, 2025). CDC. Hepatitis A vaccine. 2025. Available from: https://www.cdc.gov/hepatitis-a/vaccination/index.html (Accessed June 10, 2025). CDC. Hepatitis B vaccine. 2025. Available from: https://www.cdc.gov/hepatitis-b/vaccination/index.html (Accessed June 10, 2025). CDC. HIV infection among heterosexuals at increased risk--United States, 2010. MMWR Morb Mortal Wkly Rep 2013;62:183-8. CDC. Viral hepatitis among people with HIV. 2025. Available from: https://www.cdc.gov/hepatitis/hcp/populations-settings/hiv.html (Accessed June 10, 2025. Clinical info HIV.gov. Considerations for Antiretroviral Use in People With Coinfections, Hepatitis B Virus/HIV Coinfection. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/hepatitis-b-virus-hiv-coinfection (Accessed July 21, 2025). Cornberg M, Sandmann L, Jaroszewicz J et al. J Hepatol 2025; doi: 10.1016/j.jhep.2025.03.018. Coukan F, Murray KK, Papageorgiou V et al. HIV Med 2023;24:893–913. DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025). GHTF. Breaking the silence: combating stigma and misinformation in the fight against hepatitis. 2024. Available from: https://www.globalhep.org/news-blogs/breaking-silence-combating-stigma-and-misinformation-fight-against-hepatitis (Accessed June 10, 2025) Grieb SM, Harris R, Rosecrans A et al. Ann Med 2022;54:138–49. HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed June 10, 2025). Kitt H et al. HIV testing, PrEP, new HIV diagnoses and care outcomes for people accessing HIV services: 2024 report. 2024. Available from https://www.gov.uk/government/statistics/hiv-annual-data-tables/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2024-report (Accessed June 10, 2025) Mayer KH, Agwu A, Malebranche D. Adv Ther 2020;37:1778–811. Mohareb AM, Larmarange J, Kim AY et al. Lancet HIV 2022;9:e585–e94. Moorman AC, Bixler D, Teshale EH et al. Public Health Rep 2023; doi: 10.1177/00333549231181348 Orkin, C. Open Forum Infect Dis 2024;11:ofad668. Post Z et al. Clin Liver Dis 2023;27:973-84 Saleska JL, Lee SJ. JAMA Pediatr 2020;174:1133–34. Symum H, Van Handel M, Sandul A et al. Prev Med Rep 2024;44:102777. UNAIDS. Global HIV & AIDS statistics — Fact sheet. 2025. Available from: https://www.unaids.org/en/resources/fact-sheet (...
    Voir plus Voir moins
    21 min
  • History of the AIDS Epidemic Including HIV Drug Resistance

    History of the AIDS Epidemic Including HIV Drug Resistance
    Nov 11 2025
    Overview: In this episode, Dr Joel Gallant gives a history of antiretroviral therapy and HIV drug resistance, drawing on his personal and professional experience beginning in the early 1980s. The views expressed are those of the panelist and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2023 and the content reflects the information available at that time. Guest: Joel Gallant, MD, MPH For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus References AIDSVu.org. New HIV diagnoses. 2023. Available from: https://aidsvu.org/local-data/united-states/south/ (Accessed May 19, 2025) AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Alonso A, de Irala J. Strategies in HIV prevention: the A-B-C approach. Lancet 2004;364:1033. Available from: https://doi.org/10.1016/s0140-6736(04)17050-5 Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999–5008. Available from: https://doi.org/10.1128/jvi.75.11.4999-5008.2001 Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–71. Available from: https://doi.org/10.1126/science.6189183 Bayer R, Edington C. HIV testing, human rights, and global AIDS policy: exceptionalism and its discontents. J Health Polit Policy Law 2009;34:301–23. Available from: https://doi.org/10.1215/03616878-2009-002 Centers for Disease Control and Prevention. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm Centers for Disease Control and Prevention. Preventing HIV. 2024. Available from: https://www.cdc.gov/hiv/prevention/index.html (Accessed May 22, 2025) Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. Available from: https://doi.org/10.1056/NEJMoa1105243 Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015;13:e1002251. Available from: https://doi.org/10.1371/journal.pbio.1002251 Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy (Accessed May 19, 2025) Dragovic G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac J Trop Biomed 2013;3:422–425. Available from: https://doi.org/10.1016%2FS2221-1691(13)60091-X Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662–9. Available from: https://doi.org/10.1056/nejm199512213332502 Gandhi RT, Tashima KT, Smeaton LM et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J Infect Dis 2020;221:1407–15. Available from: https://doi.org/10.1093/infdis/jiz281 Getting to Zero San Francisco. HIV epidemiology annual report 2017. 2022. Available from: https://gettingtozerosf.org/getting-to-zero-resources/hiv-report-2017/ (Accessed May 22, 2025) Global Fund. About the Global Fund. 2024. Available from: https://www.theglobalfund.org/en/about-the-global-fund/ (Accessed May 19, 2025) Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429–41. Available from: https://doi.org/10.1056/NEJMoa0803152 Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734–9. Available from: https://doi.org/10.1056/nejm199709113371102 Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b47 HIV Prevention Trials Network. HPTN 052. 2023. Available from: https://www.hptn.org/research/studies/hptn052 (Accessed May 19, 2025) HIV.gov. HIV and AIDS timeline. 2024. Available from: https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline/ (Accessed May 19, 2025) HIVinfo.NIH.gov. FDA approval of HIV ...
    Voir plus Voir moins
    16 min
  • How Blood Tests are Revolutionizing Alzheimer’s Diagnosis

    How Blood Tests are Revolutionizing Alzheimer’s Diagnosis
    Jan 15 2025

    Overview: Explore the evolving landscape of Alzheimer’s diagnosis, where blood tests are emerging as a critical tool in clinical practice. In this episode, we’ll examine how these tests add value to traditional diagnostic methods and the latest research validating their accuracy. Join us to discover the potential of blood tests in transforming Alzheimer’s diagnosis. Guest: Suzanne E. Schindler, MD, PhD, Associate Professor of Neurology, Washington University School of Medicine For more information, please visit: https://www.pri-med.com/clinical-resources/podcast/ceoi-alzheimers-diagnostics-pt-1

    Voir plus Voir moins
    14 min
  • From Lab to Practice: Integrating Alzheimer’s Blood Tests into Primary Practice

    From Lab to Practice: Integrating Alzheimer’s Blood Tests into Primary Practice
    Jan 15 2025

    Overview: With the foundational knowledge from Episode 1, we transition from theory to practice. As these diagnostic tools become more widespread, primary care clinicians are at the forefront of their implementation. Listeners will gain insights from real-world experiences, learning actionable strategies to overcome challenges such as logistical barriers and resource limitations. By the end of this episode, primary care clinicians will have a roadmap for implementing blood tests into their practice. Guest: Deanna Willis, MD, MBA, FAAFP, FNAP; Jared Brosch, MD For more information, please visit: https://www.pri-med.com/clinical-resources/podcast/ceoi-alzheimers-diagnostics-pt-2

    Voir plus Voir moins
    14 min
  • Navigating Ethics and Communication: Delivering Alzheimer’s Blood Test Results

    Navigating Ethics and Communication: Delivering Alzheimer’s Blood Test Results
    Jan 15 2025

    Overview: As blood tests for Alzheimer’s become more accessible, clinicians must navigate the ethical and emotional complexities of delivering life-changing results. We explore how to communicate these findings with care, manage the psychological impact on patients and families, and address uncertainty in ambiguous cases. Drawing on real-world experiences and research, discover practical guidance for balancing clinical responsibility with compassionate patient care. Guest: Michelle M. Mielke, PhD; Allyson Rosen, PhD, ABPP-CN For more information, please visit: https://www.pri-med.com/clinical-resources/podcast/ceoi-alzheimers-diagnostics-pt-3

    Voir plus Voir moins
    11 min